Benralizumab for the treatment of chronic spontaneous urticaria: a plain language summary of the ARROYO study
This Plain Language Summary of Publication article (PLSP) from Immunotherapy, explored the effectiveness and safety of benralizumab for treating chronic spontaneous urticaria (CSU), a long-lasting skin condition that causes itchy hives with no known cause. Some patients don’t respond well to antihistamines or the currently approved biologic, omalizumab. Benralizumab, an injectable biologic that reduces inflammation by targeting eosinophils, was tested in patients with CSU who didn’t improve with antihistamines.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial’ and was published in the British Journal of Dermatology.
Visit Oxford Academic using the link to read the original article.